AstraZeneca PLCAZNNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank41
Year-over-Year Change
Year-over-year net income growth rate
Percentile
P41
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -8.17% |
| Q3 2025 | 3.39% |
| Q2 2025 | -15.98% |
| Q1 2025 | 94.40% |
| Q4 2024 | 4.97% |
| Q3 2024 | -25.84% |
| Q2 2024 | -11.56% |
| Q1 2024 | 126.98% |
| Q4 2023 | -30.13% |
| Q3 2023 | -24.42% |
| Q2 2023 | 0.83% |
| Q1 2023 | 100.11% |
| Q4 2022 | -45.06% |
| Q3 2022 | 355.56% |
| Q2 2022 | -6.74% |
| Q1 2022 | 211.24% |
| Q4 2021 | 79.00% |
| Q3 2021 | -400.36% |
| Q2 2021 | -64.77% |
| Q1 2021 | 54.25% |
| Q4 2020 | 56.17% |
| Q3 2020 | -14.29% |
| Q2 2020 | -3.08% |
| Q1 2020 | 149.20% |
| Q4 2019 | 4.68% |
| Q3 2019 | 130.00% |
| Q2 2019 | -78.08% |
| Q1 2019 | -42.65% |
| Q4 2018 | 139.91% |
| Q3 2018 | 23.14% |
| Q2 2018 | 2.94% |
| Q1 2018 | -73.87% |
| Q4 2017 | 89.65% |
| Q3 2017 | 43.82% |
| Q2 2017 | -11.17% |
| Q1 2017 | -70.85% |
| Q4 2016 | 81.66% |
| Q3 2016 | 33900.00% |
| Q2 2016 | -100.46% |
| Q1 2016 | -20.05% |